P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000846612.13339.9e |
| _version_ | 1827336845510311936 |
|---|---|
| author | T. Facon S. K. Kumar T. Plesner P. Moreau N. Bahlis H. Goldschmidt M. O’Dwyer A. Perrot C. P. Venner K. Weisel J. R. Mace N. Raje M. Tiab M. Macro L. Frenzel X. Leleu H. Pei F. Borgsten S. Z. Usmani |
| author_facet | T. Facon S. K. Kumar T. Plesner P. Moreau N. Bahlis H. Goldschmidt M. O’Dwyer A. Perrot C. P. Venner K. Weisel J. R. Mace N. Raje M. Tiab M. Macro L. Frenzel X. Leleu H. Pei F. Borgsten S. Z. Usmani |
| author_sort | T. Facon |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:41:26Z |
| format | Article |
| id | doaj.art-4876a1bd32354e4aa5e92f10a1ddfc25 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:41:26Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-4876a1bd32354e4aa5e92f10a1ddfc252024-03-02T03:51:55ZengWileyHemaSphere2572-92412022-06-01682682710.1097/01.HS9.0000846612.13339.9e202206003-00826P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDYT. Facon0S. K. Kumar1T. Plesner2P. Moreau3N. Bahlis4H. Goldschmidt5M. O’Dwyer6A. Perrot7C. P. Venner8K. Weisel9J. R. Mace10N. Raje11M. Tiab12M. Macro13L. Frenzel14X. Leleu15H. Pei16F. Borgsten17S. Z. Usmani181 University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France2 Department of Hematology, Mayo Clinic Rochester, Rochester, MN, United States of America3 Vejle Hospital and University of Southern Denmark, Vejle, Denmark4 Hematology Department, University Hospital Hôtel-Dieu, Nantes, France5 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada6 University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany7 Department of Medicine/Haematology, NUI, Galway, Ireland8 CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France9 Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada10 Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany11 Florida Cancer Specialists, St. Petersburg, FL12 Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA, United States of America13 CHD Vendée, La Roche sur Yon14 Centre Hospitalier Universitaire (CHU) de Caen, Caen15 Department of Clinical Haematology, Hopital Necker-Enfants Malades, Paris16 CHU Poitiers, Hôpital la Milétrie, Poitiers, France17 Janssen Research & Development, LLC, Titusville, NJ, United States of America18 Janssen-Cilag, Birkerød, Denmark19 Memorial Sloan Kettering Cancer Center, New York, NY, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000846612.13339.9e |
| spellingShingle | T. Facon S. K. Kumar T. Plesner P. Moreau N. Bahlis H. Goldschmidt M. O’Dwyer A. Perrot C. P. Venner K. Weisel J. R. Mace N. Raje M. Tiab M. Macro L. Frenzel X. Leleu H. Pei F. Borgsten S. Z. Usmani P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY HemaSphere |
| title | P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_full | P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_fullStr | P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_full_unstemmed | P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_short | P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY |
| title_sort | p936 time to response duration of response and patient reported outcomes with daratumumab plus rd vs rd alone in transplant ineligible patients with ndmm subgroup analysis of the phase 3 maia study |
| url | http://journals.lww.com/10.1097/01.HS9.0000846612.13339.9e |
| work_keys_str_mv | AT tfacon p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT skkumar p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT tplesner p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT pmoreau p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT nbahlis p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT hgoldschmidt p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT modwyer p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT aperrot p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT cpvenner p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT kweisel p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT jrmace p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT nraje p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT mtiab p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT mmacro p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT lfrenzel p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT xleleu p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT hpei p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT fborgsten p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy AT szusmani p936timetoresponsedurationofresponseandpatientreportedoutcomeswithdaratumumabplusrdvsrdaloneintransplantineligiblepatientswithndmmsubgroupanalysisofthephase3maiastudy |